Target Price | CHF297.84 |
Price | CHF291.30 |
Potential | 2.25% |
Number of Estimates | 21 |
21 Analysts have issued a price target Roche 2026 . The average Roche target price is CHF297.84. This is 2.25% higher than the current stock price. The highest price target is CHF459.90 57.88% , the lowest is CHF237.35 18.52% . | |
A rating was issued by 26 analysts: 12 Analysts recommend Roche to buy, 8 to hold and 6 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Roche stock has an average upside potential 2026 of 2.25% . Most analysts recommend the Roche stock at Purchase. |
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion CHF | 60.50 | 63.25 |
3.03% | 4.56% | |
EBITDA Margin | 33.78% | 39.66% |
5.15% | 17.39% | |
Net Margin | 13.68% | 25.07% |
30.13% | 83.23% |
20 Analysts have issued a sales forecast Roche 2025 . The average Roche sales estimate is CHF63.3b . This is 4.56% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF68.2b 12.75% , the lowest is CHF59.9b 1.03% .
This results in the following potential growth metrics:
2024 | CHF60.5b | 3.03% |
---|---|---|
2025 | CHF63.3b | 4.56% |
2026 | CHF65.4b | 3.32% |
2027 | CHF67.5b | 3.29% |
2028 | CHF69.6b | 3.07% |
2029 | CHF73.8b | 6.07% |
2030 | CHF77.1b | 4.46% |
2031 | CHF82.4b | 6.94% |
2032 | CHF84.5b | 2.49% |
18 Analysts have issued an Roche EBITDA forecast 2025. The average Roche EBITDA estimate is CHF25.1b . This is 22.75% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF27.6b 34.93% , the lowest is CHF22.3b 9.13% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | CHF20.4b | 8.34% |
---|---|---|
2025 | CHF25.1b | 22.75% |
2026 | CHF26.1b | 4.02% |
2027 | CHF27.0b | 3.36% |
2028 | CHF29.4b | 8.86% |
2029 | CHF32.4b | 10.42% |
2030 | CHF34.7b | 6.96% |
2031 | CHF37.1b | 7.08% |
2032 | CHF38.8b | 4.46% |
2024 | 33.78% | 5.15% |
---|---|---|
2025 | 39.66% | 17.39% |
2026 | 39.93% | 0.68% |
2027 | 39.96% | 0.08% |
2028 | 42.20% | 5.61% |
2029 | 43.93% | 4.10% |
2030 | 44.98% | 2.39% |
2031 | 45.04% | 0.13% |
2032 | 45.91% | 1.93% |
21 Roche Analysts have issued a net profit forecast 2025. The average Roche net profit estimate is CHF15.9b . This is 91.59% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF17.8b 115.54% , the lowest is CHF12.9b 55.95% .
This results in the following potential growth metrics and future Net Margins:
2024 | CHF8.3b | 28.01% |
---|---|---|
2025 | CHF15.9b | 91.59% |
2026 | CHF16.7b | 5.00% |
2027 | CHF17.6b | 5.89% |
2028 | CHF18.9b | 7.00% |
2029 | CHF20.2b | 7.09% |
2030 | CHF21.5b | 6.24% |
2031 | CHF23.1b | 7.49% |
2032 | CHF23.7b | 2.79% |
2024 | 13.68% | 30.13% |
---|---|---|
2025 | 25.07% | 83.23% |
2026 | 25.48% | 1.64% |
2027 | 26.12% | 2.51% |
2028 | 27.11% | 3.79% |
2029 | 27.38% | 1.00% |
2030 | 27.84% | 1.68% |
2031 | 27.99% | 0.54% |
2032 | 28.07% | 0.29% |
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share CHF | 10.32 | 19.94 |
27.83% | 93.22% | |
P/E | 14.61 | |
EV/Sales | 3.93 |
21 Analysts have issued a Roche forecast for earnings per share. The average Roche EPS is CHF19.94 . This is 93.22% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF22.43 117.34% , the lowest is CHF16.23 57.27% .
This results in the following potential growth metrics and future valuations:
2024 | CHF10.32 | 27.83% |
---|---|---|
2025 | CHF19.94 | 93.22% |
2026 | CHF20.93 | 4.96% |
2027 | CHF22.17 | 5.92% |
2028 | CHF23.72 | 6.99% |
2029 | CHF25.40 | 7.08% |
2030 | CHF26.98 | 6.22% |
2031 | CHF29.01 | 7.52% |
2032 | CHF29.81 | 2.76% |
Current | 28.23 | 44.57% |
---|---|---|
2025 | 14.61 | 48.24% |
2026 | 13.92 | 4.72% |
2027 | 13.14 | 5.60% |
2028 | 12.28 | 6.54% |
2029 | 11.47 | 6.60% |
2030 | 10.79 | 5.93% |
2031 | 10.04 | 6.95% |
2032 | 9.77 | 2.69% |
Based on analysts' sales estimates for 2025, the Roche stock is valued at an EV/Sales of 3.93 and an P/S ratio of 3.66 .
This results in the following potential growth metrics and future valuations:
Current | 4.11 | 1.99% |
---|---|---|
2025 | 3.93 | 4.37% |
2026 | 3.80 | 3.21% |
2027 | 3.68 | 3.19% |
2028 | 3.57 | 2.98% |
2029 | 3.37 | 5.72% |
2030 | 3.23 | 4.26% |
2031 | 3.02 | 6.49% |
2032 | 2.94 | 2.43% |
Current | 3.82 | 6.30% |
---|---|---|
2025 | 3.66 | 4.36% |
2026 | 3.54 | 3.21% |
2027 | 3.43 | 3.19% |
2028 | 3.32 | 2.98% |
2029 | 3.13 | 5.72% |
2030 | 3.00 | 4.27% |
2031 | 2.81 | 6.49% |
2032 | 2.74 | 2.43% |
Analyst | Rating | Action | Date |
---|---|---|---|
DAY BY DAY |
Hold
➜
Buy
|
Upgrade | Sep 08 2025 |
HSBC GLOBAL INVESTMENT RESEARCH |
Hold
➜
Hold
|
Unchanged | Aug 25 2025 |
TD COWEN |
Hold
➜
Hold
|
Unchanged | Aug 12 2025 |
BERENBERG |
Hold
➜
Hold
|
Unchanged | Aug 11 2025 |
ROTHSCHILD & CO REDBURN |
Buy
➜
Buy
|
Unchanged | Aug 04 2025 |
DZ BANK |
Buy
➜
Buy
|
Unchanged | Jul 28 2025 |
LANDESBANK BADEN-WUERTTEMBERG |
Buy
➜
Buy
|
Unchanged | Jul 25 2025 |
Analyst Rating | Date |
---|---|
Upgrade
DAY BY DAY:
Hold
➜
Buy
|
Sep 08 2025 |
Unchanged
HSBC GLOBAL INVESTMENT RESEARCH:
Hold
➜
Hold
|
Aug 25 2025 |
Unchanged
TD COWEN:
Hold
➜
Hold
|
Aug 12 2025 |
Unchanged
BERENBERG:
Hold
➜
Hold
|
Aug 11 2025 |
Unchanged
ROTHSCHILD & CO REDBURN:
Buy
➜
Buy
|
Aug 04 2025 |
Unchanged
DZ BANK:
Buy
➜
Buy
|
Jul 28 2025 |
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Buy
➜
Buy
|
Jul 25 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.